| Literature DB >> 35167298 |
Qinheng Zheng1, D Matthew Peacock1, Kevan M Shokat1.
Abstract
Since its discovery as the first human oncogene in 1983, the small GTPase KRAS has been a major target of cancer drug discovery. The paper reported in this issue describes a long-awaited small molecule drug candidate of the oncogenic KRAS (G12D) mutant for the treatment of currently incurable pancreatic cancer.Entities:
Mesh：
Substances：
Year: 2022 PMID： 35167298 DOI： 10.1021/acs.jmedchem.2c00099
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446